Go to
JCI Insight
Citations to this article
V Karanikas, … , G Thynne, I F McKenzie
Published December 1, 1997
Citation Information: J Clin Invest. 1997;100(11):2783-2792. https://doi.org/10.1172/JCI119825.
Citation Information: J Clin Invest. 1997;100(11):2783-2792. https://doi.org/10.1172/JCI119825.
Abstract
Research Article
Authors
V Karanikas, L A Hwang, J Pearson, C S Ong, V Apostolopoulos, H Vaughan, P X Xing, G Jamieson, G Pietersz, B Tait, R Broadbent, G Thynne, I F McKenzie
Total citations by year
Citation information
Citations to this article (202)
| Title and authors | Publication | Year |
|---|---|---|
|
Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy.
Tong X, Dong C, Liang S |
Journal of Cancer | 2024 |
|
Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective
Liu D, Liu L, Li X, Wang S, Wu G, Che X |
Vaccines | 2024 |
|
The Mucin Family of Proteins: Candidates as Potential Biomarkers for Colon Cancer.
Cox KE, Liu S, Lwin TM, Hoffman RM, Batra SK, Bouvet M |
Cancers | 2023 |
|
Potential association factors for developing effective peptide-based cancer vaccines
Jiang C, Li J, Zhang W, Zhuang Z, Liu G, Hong W, Li B, Zhang X, Chao CC |
Frontiers in immunology | 2022 |
|
Advances in the Immunomodulatory Properties of Glycoantigens in Cancer.
da Costa V, Freire T |
Cancers | 2022 |
|
MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization.
Son HY, Jeong HK, Apostolopoulos V, Kim CW |
International journal of immunopathology and pharmacology | 2022 |
|
Peptide-Drug Conjugates: A New Hope for Cancer Management.
Chavda VP, Solanki HK, Davidson M, Apostolopoulos V, Bojarska J |
Molecules (Basel, Switzerland) | 2022 |
|
Post-Translational Modifications in Tumor-Associated Antigens as a Platform for Novel Immuno-Oncology Therapies.
Srivastava AK, Guadagnin G, Cappello P, Novelli F |
Cancers | 2022 |
|
Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action
C Pifferi, R Fuentes, A Fernández-Tejada |
Nature Reviews Chemistry | 2021 |
|
Recent advances in combination of microneedles and nanomedicines for lymphatic targeted drug delivery
AD Permana, F Nainu, K Moffatt, E Larrañeta, RF Donnelly |
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology | 2021 |
|
Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review
E Raoufi, B Bahramimeimandi, M Salehi-Shadkami, P Chaosri, MR Mozafari |
Biomedicines | 2021 |
|
MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy
F Maleki, F Rezazadeh, K Varmira |
Molecular Pharmaceutics | 2021 |
|
Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan.
Matsoukas JM, Ligielli I, Chasapis CT, Kelaidonis K, Apostolopoulos V, Mavromoustakos T |
Brain Sciences | 2021 |
|
An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer
H Yu, C Ye, J Li, C Pan, W Lin, H Chen, Z Zhou, Y Ye |
Experimental Cell Research | 2020 |
|
Carbohydrate Conjugates in Vaccine Developments
S Lang, X Huang |
Frontiers in Chemistry | 2020 |
|
Vaccine development against methamphetamine drug addiction
K Hossain, M Hassanzadeganroudsari, K Nurgali, V Apostolopoulos |
Expert Review of Vaccines | 2020 |
|
The Long Road of Immunotherapeutics against Multiple Sclerosis
V Apostolopoulos, A Rostami, J Matsoukas |
Brain Sciences | 2020 |
|
The Use of Electrochemical Voltammetric Techniques and High-Pressure Liquid Chromatography to Evaluate Conjugation Efficiency of Multiple Sclerosis Peptide-Carrier Conjugates
E Deskoulidis, S Petrouli, V Apostolopoulos, J Matsoukas, E Topoglidis |
Brain Sciences | 2020 |
|
Cancer-associated mucins: role in immune modulation and metastasis
R Bhatia, SK Gautam, A Cannon, C Thompson, BR Hall, A Aithal, K Banerjee, M Jain, JC Solheim, S Kumar, SK Batra |
Cancer and Metastasis Reviews | 2019 |
|
The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer
V Barriga, N Kuol, K Nurgali, V Apostolopoulos |
Cancers | 2019 |
|
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
Z Xu, D Guo, Z Jiang, R Tong, P Jiang, L Bai, L Chen, Y Zhu, C Guo, J Shi, D Yu |
European Journal of Medicinal Chemistry | 2019 |
|
Protective Epitope Discovery and the Design of MUC1 Based Vaccine for Effective Tumor Protections in Immunotolerant Mice
X Wu, Z Yin, C McKay, C Pett, J Yu, M Schorlemer, T Gohl, S Sungsuwan, S Ramadan, C Baniel, A Allmon, R Das, U Westerlind, MG Finn, X Huang |
Journal of the American Chemical Society | 2018 |
|
Immune suppression and reversal of the suppressive tumor microenvironment
K Shimizu, T Iyoda, M Okada, S Yamasaki, S Fujii |
International Immunology | 2018 |
|
Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines
D Dinther, DA Stolk, R de Ven, Y Kooyk, TD de Gruijl, JM Haan |
Journal of leukocyte biology | 2017 |
|
Immunotherapy for Gastrointestinal Cancer
D Kerr, R Johnson |
Immunotherapy for Gastrointestinal Cancer | 2017 |
|
Multiple Sclerosis: Immunopathology and Treatment Update
N Dargahi, M Katsara, T Tselios, ME Androutsou, M Courten, J Matsoukas, V Apostolopoulos |
Brain Sciences | 2017 |
|
Mannosylated T/Tn with Freund’s adjuvant induces cellular immunity
HY Son, V Apostolopoulos, CW Kim |
International journal of immunopathology and pharmacology | 2017 |
|
mRNA vaccine delivery using lipid nanoparticles
AM Reichmuth, MA Oberli, A Jeklenec, R Langer, D Blankschtein |
Therapeutic Delivery | 2016 |
|
Holland-Frei Cancer Medicine
RC Bast, WN Hait, DW Kufe, RR Weichselbaum, JF Holland, CM Croce, M Piccart-Gebart, H Wang, WK Hong, RE Pollock |
Holland-Frei Cancer Medicine | 2016 |
|
Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer
E Scheid, P Major, A Bergeron, OJ Finn, RD Salter, R Eady, B Yassine-Diab, D Favre, Y Peretz, C Landry, S Hotte, SD Mukherjee, GA Dekaban, C Fink, PJ Foster, J Gaudet, J Gariepy, RP Sekaly, L Lacombe, Y Fradet, R Foley |
Cancer immunology research | 2016 |
|
mRNA vaccine delivery using lipid nanoparticles
AM Reichmuth, MA Oberli, A Jaklenec, R Langer, D Blankschtein |
Therapeutic Delivery | 2016 |
|
Molecular Pathways: Mucins and Drug Delivery in Cancer
CV Rao, NB Janakiram, A Mohammed |
Clinical cancer research | 2016 |
|
T/Tn immunotherapy avoiding immune deviation
HY Son, V Apostolopoulos, CW Kim |
International journal of immunopathology and pharmacology | 2016 |
|
MUC1 (CD227): a multi-tasked molecule
V Apostolopoulos, L Stojanovska, SE Gargosky |
Cellular and Molecular Life Sciences | 2015 |
|
Triple-negative breast cancer: investigating potential molecular therapeutic target
A Papa, D Caruso, S Tomao, L Rossi, E Zaccarelli, F Tomao |
Expert Opinion on Therapeutic Targets | 2015 |
|
Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines
C Goyvaerts, K Breckpot |
Journal of Immunology Research | 2015 |
|
Genetically engineered mucin mouse models for inflammation and cancer
S Joshi, S Kumar, S Bafna, S Rachagani, KU Wagner, M Jain, SK Batra |
Cancer and Metastasis Reviews | 2015 |
|
Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?
T Mizuguchi, T Torigoe, F Satomi, H Shima, G Kutomi, S Ota, M Ishii, H Hayashi, S Asakura, Y Hirohashi, M Meguro, Y Kimura, T Nishidate, K Okita, M Ishino, A Miyamoto, M Hatakenaka, N Sato, K Hirata |
Surgery Today | 2015 |
|
Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis
S Day, T Tselios, ME Androutsou, A Tapeinou, I Frilligou, L Stojanovska, J Matsoukas, V Apostolopoulos |
Frontiers in immunology | 2015 |
|
Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas
Xue-Ying Su, Wei-Ya Wang, Jin-Nan Li, Dian-Ying Liao, Wei-Lu Wu, Gan-Di Li |
International journal of clinical and experimental pathology | 2015 |
|
Recent advances in the development of breast cancer vaccines
G Valabrega, A Milani, M Aglietta, D Sangiolo |
Breast cancer : targets and therapy | 2014 |
|
Dendritic cell immunotherapy: clinical outcomes
V Apostolopoulos, GA Pietersz, A Tsibanis, A Tsikkinis, L Stojanovska, IF McKenzie, S Vassilaros |
IBMS BoneKEy | 2014 |
|
A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer
PL Mitchell, MA Quinn, PT Grant, DG Allen, TW Jobling, SC White, A Zhao, V Karanikas, H Vaughan, G Pietersz, IF McKenzie, SE Gargosky, BE Loveland |
Journal for ImmunoTherapy of Cancer | 2014 |
|
A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides
T Matsushita, W Takada, K Igarashi, K Naruchi, R Miyoshi, F Garcia-Martin, M Amano, H Hinou, SI Nishimura |
Biochimica et Biophysica Acta (BBA) - General Subjects | 2014 |
|
Identifying Appropriate Colorectal Cancer-Associated Antigens for the Clinical Trials
M Choi, A Thakur |
Current Colorectal Cancer Reports | 2014 |
|
Targeting Antigens to Dendritic Cell Receptors for Vaccine Development
V Apostolopoulos, T Thalhammer, AG Tzakos, L Stojanovska |
Journal of drug delivery | 2013 |
|
MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer
A Siroy, FW Abdul-Karim, J Miedler, N Fong, P Fu, H Gilmore, J Baar |
Human Pathology | 2013 |
|
Mucins in pancreatic cancer and its microenvironment
S Kaur, S Kumar, N Momi, AR Sasson, SK Batra |
Nature Reviews Gastroenterology & Hepatology | 2013 |
|
Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan–MUC1
S Vassilaros, A Tsibanis, A Tsikkinis, GA Pietersz, IF McKenzie, V Apostolopoulos |
Immunotherapy | 2013 |
|
Colorectal cancer immunotherapy
B Xiang, AE Snook, MS Magee, SA Waldman |
Discovery medicine | 2013 |
|
Generation of hypoallergenic neoglycoconjugates for dendritic cell targeted vaccination: A novel tool for specific immunotherapy
EE Weinberger, M Himly, J Myschik, M Hauser, F Altmann, A Isakovic, S Scheiblhofer, J Thalhamer, R Weiss |
Journal of Controlled Release | 2012 |
|
Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity
K Lavrsen, CB Madsen, MG Rasch, A Woetmann, N Ødum, U Mandel, H Clausen, AE Pedersen, HH Wandall |
Glycoconjugate Journal | 2012 |
|
Carbohydrate-based cancer vaccines: target cancer with sugar bullets
CC Liu, XS Ye |
Glycoconjugate Journal | 2012 |
|
Targeting tumor antigens to dendritic cells using particulate carriers
MD Joshi, WJ Unger, G Storm, Y Kooyk, E Mastrobattista |
Journal of Controlled Release | 2012 |
|
MUC1 immunotherapy is here to stay
T Kimura, OJ Finn |
Expert Opinion on Biological Therapy | 2012 |
|
MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study
T Kimura, JR McKolanis, LA Dzubinski, K Islam, DM Potter, AM Salazar, RE Schoen, OJ Finn |
Cancer prevention research (Philadelphia, Pa.) | 2012 |
|
Immune therapy for breast cancer in 2010-hype or hope?
A Florescu, E Amir, N Bouganim, M Clemons |
Current oncology (Toronto, Ont.) | 2011 |
|
Induction of antitumor immunity by dendritic cells loaded with membrane-translocating mucin 1 Peptide antigen
S Kobukai, GJ Kremers, JG Cobb, R Baheza, J Xie, A Kuley, M Zhu, W Pham |
Translational oncology | 2011 |
|
MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma
K Kaira, H Murakami, M Serizawa, Y Koh, M Abe, Y Ohde, T Takahashi, H Kondo, T Nakajima, N Yamamoto |
Virchows Archiv | 2011 |
|
Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization
SK Singh, I Streng-Ouwehand, M Litjens, H Kalay, S Burgdorf, E Saeland, C Kurts, WW Unger, Y Kooyk |
European Journal of Immunology | 2011 |
|
MUC1 Expression in Pulmonary Metastatic Tumors: A Comparison of Primary Lung Cancer
K Kaira, T Okumura, K Nakagawa, Y Ohde, T Takahashi, H Murakami, T Naito, M Endo, H Kondo, T Nakajima, N Yamamoto |
Pathology & Oncology Research | 2011 |
|
Vaccines for Colorectal Cancer and Renal Cell Carcinoma :
K Kabaker, K Shell, HL Kaufman |
The Cancer Journal | 2011 |
|
Advances in Cancer Research
M Lemaire, S Deleu, ED Bruyne, EV Valckenborgh, E Menu, K Vanderkerken |
Advances in Cancer Research Volume 110 | 2011 |
|
Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine
V Lakshminarayanan, P Thompson, MA Wolfert, T Buskas, JM Bradley, LB Pathangey, CS Madsen, PA Cohen, SJ Gendler, GJ Boons |
Proceedings of the National Academy of Sciences | 2011 |
|
Natural and Induced Humoral Responses to MUC1
SV Mensdorff-Pouilly, M Moreno, RH Verheijen |
Cancers | 2011 |
|
Depolarized MUC1 Expression Is Closely Associated With Hypoxic Markers and Poor Outcome in Resected Non–Small Cell Lung Cancer
K Kaira, K Nakagawa, Y Ohde, T Okumura, T Takahashi, H Murakami, M Endo, H Kondo, T Nakajima, N Yamamoto |
International Journal of Surgical Pathology | 2011 |
|
Ovarian cancer immunotherapy: opportunities, progresses and challenges
B Liu, J Nash, C Runowicz, H Swede, R Stevens, Z Li |
Journal of Hematology & Oncology | 2010 |
|
Emerging vaccine therapy approaches for prostate cancer
G Sonpavde, KM Slawin, DM Spencer, JM Levitt |
Reviews in urology | 2010 |
|
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
S Oudard, O Rixe, B Beuselinck, C Linassier, E Banu, JP Machiels, M Baudard, F Ringeisen, T Velu, MA Lefrere-Belda, JM Limacher, WH Fridman, M Azizi, B Acres, E Tartour |
Cancer Immunology, Immunotherapy | 2010 |
|
Number of Treatment Cycles Influences Development of Cytotoxic T Cells in Metastatic Breast Cancer Patients – A Phase I/II Study
SE Wright, KA Rewers-Felkins, IS Quinlin, CA Phillips, M Townsend, R Philip, P Zorsky, P Klug, L Dai, M Hussain, AA Thomas, C Sundaramurthy |
Immunological Investigations | 2010 |
|
Analysis of a Cholera Toxin B Subunit (CTB) and Human Mucin 1 (MUC1) Conjugate Protein in a MUC1 Tolerant Mouse Model
J Pinkhasov, ML Alvarez, LB Pathangey, TL Tinder, HS Mason, AM Walmsley, SJ Gendler, P Mukherjee |
Cancer Immunology, Immunotherapy | 2010 |
|
Topley & Wilson's Microbiology and Microbial Infections
TG Harrison |
Topley & Wilson's Microbiology and Microbial Infections | 2010 |
|
MUC1-based recombinant Bacillus Calmette–Guerin vaccines as candidates for breast cancer immunotherapy
S Yuan, C Shi, L Liu, W Han |
Expert Opinion on Biological Therapy | 2010 |
|
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, Tartour E |
Cancer Immunology, Immunotherapy | 2010 |
|
Tumor Vaccines for Breast Cancer
KS Anderson |
Cancer Investigation | 2009 |
|
Immunology
WA Walker |
Current Opinion in Gastroenterology | 2009 |
|
Anti-survivin antibody responses in lung cancer
V Karanikas, S Khalil, T Kerenidi, KI Gourgoulianis, AE Germenis |
Cancer Letters | 2009 |
|
Current status of mucins in the diagnosis and therapy of cancer
S Rachagani, MP Torres, N Moniaux, SK Batra |
BioFactors (Oxford, England) | 2009 |
|
Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy
J Liu, L Gunn, R Hansen, J Yan |
Experimental and Molecular Pathology | 2009 |
|
Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response
CA de Brito, AL Goldoni, MN Sato |
Immunotherapy | 2009 |
|
Tumor Burden Influences Cytotoxic T Cell Development in Metastatic Breast Cancer Patients—A Phase I/II Study
SE Wright, KA Rewers-Felkins, IS Quinlin, CA Phillips, M Townsend, R Philip, P Zorsky, P Klug, L Dai, M Hussain, AA Thomas, C Sundaramurthy |
Immunological Investigations | 2009 |
|
Phagocyte-Pathogen Interactions: Macrophages and the Host Response to Infection
DG Russell, S Gordon |
2009 | |
|
Mannan-Abeta28conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice
I Petrushina, A Ghochikyan, M Mkrtichyan, G Mamikonyan, N Movsesyan, R Ajdari, V Vasilevko, A Karapetyan, A Lees, MG Agadjanyan, DH Cribbs |
Journal of Neuroinflammation | 2008 |
|
Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors
CK Tang, KC Sheng, V Apostolopoulos, GA Pietersz |
Expert Review of Vaccines | 2008 |
|
Mannose-targeted systems for the delivery of therapeutics
JM Irache, HH Salman, C Gamazo, S Espuelas |
Expert Opinion on Drug Delivery | 2008 |
|
Mannosylation of mutated MBP83–99 peptides diverts immune responses from Th1 to Th2
M Katsara, E Yuriev, PA Ramsland, G Deraos, T Tselios, J Matsoukas, V Apostolopoulos |
Molecular Immunology | 2008 |
|
Mucin-type O-glycosylation and its potential use in drug and vaccine development
MA Tarp, H Clausen |
Biochimica et Biophysica Acta (BBA) - General Subjects | 2008 |
|
Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses
CK Tang, KC Sheng, D Pouniotis, S Esparon, HY Son, CW Kim, GA Pietersz, V Apostolopoulos |
Vaccine | 2008 |
|
Strategies used for MUC1 immunotherapy: human clinical studies
CK Tang, M Katsara, V Apostolopoulos |
Expert Review of Vaccines | 2008 |
|
Peptide-based vaccines for cancer: realizing their potential
S Kanodia, WM Kast |
Expert Review of Vaccines | 2008 |
|
Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies
I Atreya, MF Neurath |
Expert Review of Anticancer Therapy | 2008 |
|
Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicityin vitro andin vivo
KC Sheng, M Kalkanidis, DS Pouniotis, S Esparon, CK Tang, V Apostolopoulos, GA Pietersz |
European Journal of Immunology | 2008 |
|
Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens
Y Perrie, AR Mohammed, DJ Kirby, SE McNeil, VW Bramwell |
International Journal of Pharmaceutics | 2008 |
|
Cancer Immunology
OJ Finn |
New England Journal of Medicine | 2008 |
|
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
PJ Tacken, IJ de Vries, R Torensma, CG Figdor |
Nature Reviews Immunology | 2007 |
|
Mannan-mediated gene delivery for cancer immunotherapy
CK Tang, J Lodding, G Minigo, DS Pouniotis, M Plebanski, A Scholzen, IF McKenzie, GA Pietersz, V Apostolopoulos |
Immunology | 2007 |
|
Vaccine immunotherapy in breast cancer treatment: promising, but still early
G Curigliano, G Spitaleri, M Dettori, M Locatelli, E Scarano, A Goldhirsch |
Expert Review of Anticancer Therapy | 2007 |
|
Cancer vaccines: a promising cancer therapy against all odds
AW Silk, OJ Finn |
Future Oncology | 2007 |
|
Vaccine therapy for prostate cancer
G Sonpavde, DM Spencer, KM Slawin |
Urologic Oncology: Seminars and Original Investigations | 2007 |
|
Immunology and breast cancer: Therapeutic cancer vaccines
G Curigliano, M Rescigno, A Goldhirsch |
The Breast | 2007 |
|
The Biology of Dendritic Cells and HIV Infection
S Gessani, F Belardelli |
2007 | |
|
Receptor-Mediated Delivery of Antigens to Dendritic Cells: Anticancer Applications
O Proudfoot, V Apostolopoulos, GA Pietersz |
Molecular Pharmaceutics | 2007 |
|
Therapeutic Vaccines for Prostate Cancer
CP Tarassoff, PM Arlen, JL Gulley |
The oncologist | 2006 |
|
Translational Medicine
JV Tricoli |
Prostate Cancer: Translational and Emerging Therapies | 2006 |
|
Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates
A Ghochikyan, I Petrushina, A Lees, V Vasilevko, N Movsesyan, A Karapetyan, MG Agadjanyan, DH Cribbs |
DNA and Cell Biology | 2006 |
|
Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells
KC Sheng, DS Pouniotis, MD Wright, CK Tang, E Lazoura, GA Pietersz, V Apostolopoulos |
Immunology | 2006 |
|
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
V Apostolopoulos, GA Pietersz, A Tsibanis, A Tsikkinis, H Drakaki, BE Loveland, SJ Piddlesden, M Plebanski, DS Pouniotis, MN Alexis, IF McKenzie, S Vassilaros |
Breast Cancer Research | 2006 |
|
Targeting antigens to dendritic cells in vivo
PJ Tacken, R Torensma, CG Figdor |
Immunobiology | 2006 |
|
Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping
M Doi, A Yokoyama, K Kondo, H Ohnishi, N Ishikawa, N Hattori, N Kohno |
Cancer Science | 2006 |
|
Pathogen recognition and development of particulate vaccines: Does size matter?
SD Xiang, A Scholzen, G Minigo, C David, V Apostolopoulos, PL Mottram, M Plebanski |
Methods | 2006 |
|
The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2
MS Mitchell, TA Lund, AK Sewell, FM Marincola, E Paul, K Schroder, DB Wilson, J Kan-Mitchell |
Cancer Immunology, Immunotherapy | 2006 |
|
A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer
S Nagai, K Takenaka, M Sonobe, E Ogawa, H Wada, F Tanaka |
Journal of Thoracic Oncology | 2006 |
|
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
V Apostolopoulos, GA Pietersz, A Tsibanis, A Tsikkinis, H Drakaki, BE Loveland, SJ Piddlesden, M Plebanski, DS Pouniotis, MN Alexis, IF McKenzie, S Vassilaros |
Breast Cancer Research | 2006 |
|
Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat
MA Tarp, AL Sørensen, U Mandel, H Paulsen, J Burchell, J Taylor-Papadimitriou, H Clausen |
Glycobiology | 2006 |
|
The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2.
Mitchell MS, Lund TA, Sewell AK, Marincola FM, Paul E, Schroder K, Wilson DB, Kan-Mitchell J |
Cancer Immunology, Immunotherapy | 2006 |
|
Anti‐tumor effect of the anti‐KL‐6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping
Doi M, Yokoyama A, Kondo K, Ohnishi H, Ishikawa N, Hattori N, Kohno N |
Cancer Science | 2006 |
|
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
DH Dube, CR Bertozzi |
Nature Reviews Drug Discovery | 2005 |
|
Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers
B Gückel, C Rentzsch, MD Nastke, A Marmé, I Gruber, S Stevanović, S Kayser, D Wallwiener |
Journal of Cancer Research and Clinical Oncology | 2005 |
|
Yeast whole glucan particle (WGP) β-glucan in conjunction with antitumour monoclonal antibodies to treat cancer
J Yan, DJ Allendorf, B Brandley |
Expert Opinion on Biological Therapy | 2005 |
|
MUC1 as a target antigen for cancer immunotherapy
B Acres, JM Limacher |
Expert Review of Vaccines | 2005 |
|
Subtle sequence differences in a tumour-associated peptide epitope translate into major changes in antigenicity
J Persson, J Lantto, T Drakenberg, M Ohlin |
Molecular Immunology | 2005 |
|
Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy
J Stambas, SA Brown, A Gutierrez, R Sealy, W Yue, B Jones, TD Lockey, A Zirkel, P Freiden, B Brown, S Surman, C Coleclough, KS Slobod, PC Doherty, JL Hurwitz |
Vaccine | 2005 |
|
Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1
I Correa, T Plunkett, J Coleman, E Galani, E Windmill, JM Burchell, J Taylor-Papdimitriou |
International Journal of Cancer | 2005 |
|
Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen
JT Schuman, JS Grinstead, V Apostolopoulos, AP Campbell |
Biopolymers | 2005 |
|
Dendritic cell-based cancer immunotherapy targeting MUC-1
J Wierecky, M Mueller, P Brossart |
Cancer Immunology, Immunotherapy | 2005 |
|
Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker
TV Tselios, FN Lamari, I Karathanasopoulou, M Katsara, V Apostolopoulos, GA Pietersz, JM Matsoukas, NK Karamanos |
Analytical Biochemistry | 2005 |
|
Immunologic Therapies for Gastrointestinal Cancers
B Levy, JF Deeken, G Holt, JL Marshall |
Clinical Colorectal Cancer | 2005 |
|
Immunologic approaches to breast cancer treatment
MS Sabel, MA Nehs |
Surgical oncology clinics of North America | 2005 |
|
Breast cancer vaccines: a clinical reality or fairy tale?
G Curigliano, G Spitaleri, E Pietri, M Rescigno, F Braud, A Cardillo, E Munzone, A Rocca, G Bonizzi, V Brichard, L Orlando, A Goldhirsch |
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO | 2005 |
|
Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance
AL Sørensen, CA Reis, MA Tarp, U Mandel, K Ramachandran, V Sankaranarayanan, T Schwientek, R Graham, J Taylor-Papadimitriou, MA Hollingsworth, J Burchell, H Clausen |
Glycobiology | 2005 |
|
Tumor Immunology and Cancer Vaccines
SN Khleif |
2005 | |
|
Antibodies against Tumor Cell Glycolipids and Proteins, but Not Mucins, Mediate Complement-Dependent Cytotoxicity
G Ragupathi, NX Liu, C Musselli, S Powell, K Lloyd, PO Livingston |
Journal of immunology (Baltimore, Md. : 1950) | 2005 |
|
Dendritic cell-based cancer immunotherapy targeting MUC-1.
Wierecky J, Mueller M, Brossart P |
Cancer Immunology, Immunotherapy | 2005 |
|
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans
ID Davis, W Chen, H Jackson, P Parente, M Shackleton, W Hopkins, Q Chen, N Dimopoulos, T Luke, R Murphy, AM Scott, E Maraskovsky, G McArthur, D MacGregor, S Sturrock, TY Tai, S Green, A Cuthbertson, D Maher, L Miloradovic, SV Mitchell, G Ritter, AA Jungbluth, YT Chen, S Gnjatic, EW Hoffman, LJ Old, JS Cebon |
Proceedings of the National Academy of Sciences | 2004 |
|
Mannose receptor-targeted vaccines
T Keler, V Ramakrishna, MW Fanger |
Expert Opinion on Biological Therapy | 2004 |
|
Peptide-based vaccines for cancer immunotherapy
JA Brinkman, SC Fausch, JS Weber, WM Kast |
Expert Opinion on Biological Therapy | 2004 |
|
Colorectal cancer vaccines: Principles, results, and perspectives
S Mocellin, CR Rossi, M Lise, D Nitti |
Gastroenterology | 2004 |
|
Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain
T Plunkett, R Graham, I Correa, R Sewell, D Miles, J Burchell, J Taylor-Papadimitriou |
International Journal of Cancer | 2004 |
|
CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors
J Dittmann, K Keller-Matschke, T Weinschenk, T Kratt, T Heck, HD Becker, S Stevanović, HG Rammensee, C Gouttefangeas |
Cancer Immunology, Immunotherapy | 2004 |
|
Prognostic utility of a glycoprotein tumor-associated antigen (TA90) specific immune complex assay in patients with cancer
RK Gupta, DL Morton |
Clinical and Applied Immunology Reviews | 2004 |
|
How does the immune system attack cancer?
MA Morse, HK Lyerly, TM Clay, O Abdel-Wahab, SY Chui, J Garst, J Gollob, PM Grossi, M Kalady, PJ Mosca, M Onaitis, JH Sampson, HF Seigler, EM Toloza, D Tyler, J Vieweg, Y Yang |
Current Problems in Surgery | 2004 |
|
Mucins in cancer: protection and control of the cell surface
MA Hollingsworth, BJ Swanson |
Nature Reviews Cancer | 2004 |
|
Handbook of Cancer Vaccines
MA Morse, TM Clay, HK Lyerly |
2004 | |
|
CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors.
Dittmann J, Keller-Matschke K, Weinschenk T, Kratt T, Heck T, Becker HD, Stevanović S, Rammensee HG, Gouttefangeas C |
Cancer Immunology, Immunotherapy | 2004 |
|
An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells
C Heuser, M Ganser, A Hombach, H Brand, G Denton, FG Hanisch, H Abken |
British Journal of Cancer | 2003 |
|
Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells
M Bäckström, T Link, FJ Olson, H Karlsson, R Graham, G Picco, J Burchell, J Taylor-Papadimitriou, T Noll, GC Hansson |
Biochemical Journal | 2003 |
|
Aspects of cancer immunotherapy
IF McKenzie, V Apostolopoulos, M Plebanski, GA Pietersz, BE Loveland |
Immunology and Cell Biology | 2003 |
|
Strategies in cancer vaccines development
G Cunto-Amesty, B Monzavi-Karbassi, P Luo, F Jousheghany, T Kieber-Emmons |
International Journal for Parasitology | 2003 |
|
Cancer Chemotherapy and Biological Response Modifiers Annual
MS Turner, JR McKolanis, RK Ramanathan, DC Whitcomb, OJ Finn |
Cancer Chemotherapy and Biological Response Modifiers Annual Volume 21 | 2003 |
|
Rationale for the Clinical Development of STn-KLH (Theratope®) and Anti—MUC-1 Vaccines in Breast Cancer
D Miles, K Papazisis |
Clinical Breast Cancer | 2003 |
|
Use of the Anti-idiotype Breast Cancer Vaccine 11D10 in Conjunction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer
DE Reece, KA Foon, M Bhattarchaya-Chatterjee, D Adkins, ER Broun, DG Connaghan, JF Dipersio, HK Holland, DA Howard, GA Hale, HG Klingemann, RK Munn, A Raptis, GL Phillips |
Clinical Breast Cancer | 2003 |
|
Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors
V Vasilevko, A Ghochikyan, N Sadzikava, I Petrushina, M Tran, EP Cohen, PJ Kesslak, DH Cribbs, GL Nicolson, MG Agadjanyan |
Clinical & Experimental Metastasis | 2003 |
|
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2
S Scholl, P Squiban, N Bizouarne, M Baudin, B Acres, SV Mensdorff-Pouilly, M Shearer, P Beuzeboc, SV Belle, B Uzielly, P Pouillart, J Taylor-Papadimitriou, D Miles |
Journal of Biomedicine and Biotechnology | 2003 |
|
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer
PM Arlen, JL Gulley, KY Tsang, J Schlom |
Expert Review of Vaccines | 2003 |
|
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2
S Scholl, P Squiban, N Bizouarne, M Baudin, B Acres, S Mensdorff-Pouilly, M Shearer, P Beuzeboc, SV Belle, B Uzielly, P Pouillart, J Taylor-Papadimitriou, D Miles |
Journal of Biomedicine and Biotechnology | 2003 |
|
An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells
C Heuser, M Ganser, A Hombach, H Brand, G Denton, FG Hanisch, H Abken |
British Journal of Cancer | 2003 |
|
Oxidised mannan-listeriolysin O conjugates induce Th1/Th2 cytokine responses after intranasal immunisation
J Stambas, G Pietersz, I McKenzie, V Nagabhushanam, C Cheers |
Vaccine | 2002 |
|
Oxidised mannan as a novel adjuvant inducing mucosal IgA production
J Stambas, G Pietersz, I McKenzie, C Cheers |
Vaccine | 2002 |
|
Towards patient-specific tumor antigen selection for vaccination
HG Rammensee, T Weinschenk, C Gouttefangeas, SS Eq |
Immunological Reviews | 2002 |
|
The case for polyvalent cancer vaccines that induce antibodies
G Ragupathi, P Livingston |
Expert Review of Vaccines | 2002 |
|
Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen
O Klein, S Linn, C Davidson, A Hadary, A Shukha, J Zidan, A Eitan, AI Kook |
The Breast | 2002 |
|
Recombinant MUC1 Probe Authentically Reflects Cell-specific O -Glycosylation Profiles of Endogenous Breast Cancer Mucin: HIGH DENSITY AND PREVALENT CORE 2-BASED GLYCOSYLATION
S Müller, FG Hanisch |
The Journal of biological chemistry | 2002 |
|
Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1
C Musselli, G Ragupathi, T Gilewski, KS Panageas, Y Spinat, PO Livingston |
International Journal of Cancer | 2002 |
|
Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model
K Kontani, O Taguchi, Y Ozaki, J Hanaoka, N Tezuka, S Sawai, S Inoue, S Fujino, T Maeda, Y Itoh, K Ogasawara, H Sato, I Ohkubo, T Kudo |
Cancer Gene Therapy | 2002 |
|
Generation of potent and specific cellular immune responses via in vivo stimulation of dendritic cells by pNGVL3-hFLex plasmid DNA and immunogenic peptides
CL Fong, KM Hui |
Gene Therapy | 2002 |
|
An approach for high sensitivity detection of breast cancer by analysis of changes in structure of the cytoplasmic matrix of lymphocytes specifically induced by a specific breast tumour antigen (MUC-l/SEC)
O Klein, S Linn, A Hadari, C Davidson, A Eitan, J Zidan, AI Kook |
Breast (Edinburgh, Scotland) | 2002 |
|
Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes
K Kontani, O Taguchi, T Narita, M Izawa, N Hiraiwa, K Zenita, T Takeuchi, H Murai, S Miura, R Kannagi |
British Journal of Cancer | 2001 |
|
Interim Analysis of the Use of the Anti-Idiotype Breast Cancer Vaccine 11D10 (TriAb®) in Conjunction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer
DE Reece, KA Foon, M Battacharya-Chatterjee, D Adkins, ER Broun, DG Connaghan, JF Dipersio, HK Holland, DS Howard, GA Hale, HG Klingemann, RK Munn, A Raptis, GL Phillips |
Clinical Breast Cancer | 2001 |
|
Adenovirus-Mediated MUC1 Gene Transduction into Human Blood-Derived Dendritic Cells
K Maruyama, Y Akiyama, N Nara-Ashizawa, T Hojo, JY Cheng, H Mizuguchi, T Hayakawa, K Yamaguchi |
Journal of Immunotherapy | 2001 |
|
Cellular engineering for the production of blood components
J McCullough |
Transfusion | 2001 |
|
Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection
V Karanikas, G Thynne, P Mitchell, CS Ong, D Gunawardana, R Blum, J Pearson, J Lodding, G Pietersz, R Broadbent, B Tait, IF McKenzie |
Journal of Immunotherapy | 2001 |
|
Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer
M Palmer, J Parker, S Modi, C Butts, M Smylie, A Meikle, M Kehoe, G MacLean, M Longenecker |
Clinical Lung Cancer | 2001 |
|
Transfusion Medicine: Quo Vadis? What Has Been Achieved, What Is to Be Expected
CT Sibinga, JD Cash |
2001 | |
|
Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design
YL Yip, G Smith, J Koch, S Dübel, RL Ward |
Journal of immunology (Baltimore, Md. : 1950) | 2001 |
|
Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection
MM Soares, V Mehta, OJ Finn |
Journal of immunology (Baltimore, Md. : 1950) | 2001 |
|
MUC1, the renaissance molecule
S J Gendler |
Journal of Mammary Gland Biology and Neoplasia | 2001 |
|
Breast cancer and the immune system: opportunities and pitfalls
T A Plunkett, I Correa, D W Miles, J Taylor-Papadimitriou |
Journal of Mammary Gland Biology and Neoplasia | 2001 |
|
MUC1 in carcinoma-host interactions
K Denda-Nagai, T Irimura |
Glycoconjugate Journal | 2001 |
|
Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells
J Gong, V Apostolopoulos, D Chen, H Chen, S Koido, SJ Gendler, IF McKenzie, D Kufe |
Immunology | 2000 |
|
Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1
GA Pietersz, W Li, C Osinski, V Apostolopoulos, IF McKenzie |
Vaccine | 2000 |
|
The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan
HA Vaughan, DW Ho, V Karanikas, MS Sandrin, IF McKenzie, GA Pietersz |
Vaccine | 2000 |
|
Biological Therapy of Breast Cancer
JW Park, D Tripathy, MJ Campbell, LJ Esserman |
BioDrugs | 2000 |
|
Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses
V Apostolopoulos, N Barnes, GA Pietersz, IF McKenzie |
Vaccine | 2000 |
|
HLA class I expression on human cancer cells
BD Tait |
Human Immunology | 2000 |
|
Humoral immunity against the proline-rich peptide epitope of the IgA1 hinge region in IgA nephropathy
T Kokubo, K Hashizume, H Iwase, K Arai, A Tanaka, K Toma, K Hotta, Y Kobayashi |
Nephrology Dialysis Transplantation | 2000 |
|
Natural Autoantibody to MUC1 Is a Prognostic Indicator for Non–Small Cell Lung Cancer
Y Hirasawa, N Kohno, A Yokoyama, K Kondo, K Hiwada, M Miyake |
American journal of respiratory and critical care medicine | 2000 |
|
Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin
S Mensdorff-Pouilly, AA Verstraeten, P Kenemans, FG Snijdewint, A Kok, GJ Kamp, MA Paul, PJ Diest, S Meijer, J Hilgers |
Journal of Clinical Oncology | 2000 |
|
Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer
DE Reece, KA Foon, M Bhattacharya-Chatterjee, GA Hale, DS Howard, RK Munn, R Nath, BA Plummer, A Teitelbaum, GL Phillips |
Bone Marrow Transplantation | 2000 |
|
Human MUC1 Mucin: A Multifaceted Glycoprotein
S von Mensdorff-Pouilly, FG Snijdewint, AA Verstraeten, RH Verheijen, P Kenemans |
The International Journal of Biological Markers | 2000 |
|
Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides andn-acetylgalactosamine (GalNAc) peptides
S von Mensdorff-Pouilly, E Petrakou, P Kenemans, K van Uffelen, AA Verstraeten, FG Snijdewint, GJ van Kamp, DJ Schol, CA Reis, MR Price, PO Livingston, J Hilgers |
International Journal of Cancer | 2000 |
|
Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21
S Adluri, T Gilewski, S Zhang, V Ramnath, G Ragupathi, P Livingston |
British Journal of Cancer | 1999 |
|
Mimics and cross reactions of relevance to tumour immunotherapy
V Apostolopoulos, MS Sandrin, IF McKenzie |
Vaccine | 1999 |
|
MUC1 and cancer
J Taylor-Papadimitriou, J Burchell, DW Miles, M Dalziel |
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease | 1999 |
|
Treatment of early-stage breast cancer
TC Hurd, SB Edge, MS Kahlenberg, PC Stomper, GM Proulx, G Schwartz, V Khatri, JS Winston |
Current Problems in Cancer | 1999 |
|
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
SP Treon, JA Mollick, M Urashima, G Teoh, D Chauhan, A Ogata, N Raje, JH Hilgers, L Nadler, AR Belch, LM Pilarski, KC Anderson |
Blood | 1999 |
|
Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates
H A Vaughan, D W Ho, V A Karanikas, C S Ong, L A Hwang, J M Pearson, I F McKenzie, G A Pietersz |
Vaccine | 1999 |
|
Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice
RM Tempero, GJ Rowse, SJ Gendler, MA Hollingsworth |
International Journal of Cancer | 1999 |
|
Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies
P Brossart, KS Heinrich, G Stuhler, L Behnke, VL Reichardt, S Stevanovic, A Muhm, HG Rammensee, L Kanz, W Brugger |
Blood | 1999 |
|
Immunotherapeutic approaches for the treatment of breast cancer
K L Knutson, K Schiffman, K Rinn, M L Disis |
Journal of Mammary Gland Biology and Neoplasia | 1999 |
|
MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral
V Apostolopoulos, C Osinski, IF Mckenzie |
Nature Medicine | 1998 |
|
Mucin based breast cancer vaccines
DW Miles, J Taylor-Papadimitriou |
Expert Opinion on Investigational Drugs | 1998 |
|
Peptide mimics of a tumor antigen induce functional cytotoxic T cells
V Apostolopoulos, SA Lofthouse, V Popovski, G Chelvanayagam, MS Sandrin, FC McKenzie |
Nature Biotechnology | 1998 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)